Molecular, Cellular, and Tissue Characterization Unit

分子、细胞和组织表征单元

• 批准号: 10461044
• 负责人: William E. Gillanders
• 金额: $ 98万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10461044
• 关键词: Adjuvant Therapy; Antibodies; Apoptosis; Atlases; Biopsy; Cell Proliferation; Cells; Clinical Data; Collection; Complement; Coupled; Cytometry; DNA; Data; Data Analyses; Data Set; Diagnosis; Diffusion; Disease; Disseminated Malignant Neoplasm; Elements; Evaluation; Excision; Future; Glioblastoma; Goals; Histology; Human; Image; Imaging technology; Immune; Immune Targeting; Immunofluorescence Immunologic; Immunotherapy; Individual; Link; Location; Magnetic Resonance Imaging; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of brain; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of pancreas; Metadata; Metastatic to; Mission; Molecular; Nature; Neoadjuvant Therapy; Neoplasm Metastasis; Non-Malignant; Operative Surgical Procedures; Pancreatic Ductal Adenocarcinoma; Patient Recruitments; Patients; Phenotype; Primary Neoplasm; Procedures; Prognosis; Proteins; RNA; Recurrence; Research; Research Personnel; Resistance; Resistance development; Sampling; Signal Transduction; Site; Slide; Specimen; Stromal Cells; Structure; Technology; Time; Tissues; Training; Tumor-infiltrating immune cells; Universities; Washington; Work; aggressive breast cancer; base; cancer stem cell; cancer type; cellular imaging; design; in vivo; insight; molecular phenotype; multidimensional data; multiplexed imaging; neoplastic cell; new technology; novel; optical imaging; patient response; protein activation; protein metabolite; radiomics; response; single cell analysis; single-cell RNA sequencing; therapeutic development; therapy resistant; traditional therapy; transcriptome sequencing; treatment response; triple-negative invasive breast carcinoma; tumor; tumor microenvironment

Project Summary/Abstract: Biospecimen Unit The over-arching goal of the Biospecimen Unit for the Washington University Human Tumor Atlas Research Center (WU-HTARC) is to collect human tumor biospecimens for use by the Characterization and Data Analysis Units to construct the proposed tumor atlases. Our Biospecimen Unit will procure and bank longitudinal biopsies and excised tumors from 300-375 patients (selected from ~750 recruited patients) with a goal toward studying the transition from primary malignancy to recurrence and metastasis in conjunction with the development of therapeutic resistance in triple negative breast cancer (TNBC), glioblastoma (GBM), and pancreatic ductal adenocarcinoma (PDAC). Each of the three tumors chosen for this study poses unique challenges for both clinicians and researchers. From their often late onset of diagnosis, highly metastatic nature, challenges in achieving complete surgical resection, and primary and acquired resistance to treatment, each of these tumors represents an opportunity identified by the NCI Cancer Moonshot Initiative (CMI) to significantly advance our understanding of cancer and how to intervene on its initiation and progression. To support the overall mission of WU-HTARC, the Biospecimen Unit will perform the following: (1) identification of eligible patients at WU with TNBC, GBM, and PDAC; (2) rigorous and systemic collection of tumors, including longitudinal collection of all patients throughout their treatment course; (3) complete collection of associated clinical data and metadata; and (4) storage and processing of all samples with current and future experimental and analytical pipelines. The Biospecimen Unit will work closely with other Units within WU-HTARC to develop standard operating procedures and to make adjustments in line with the changing technologies.

项目摘要/摘要：生物循环单元 华盛顿大学人类肿瘤研究的生物循环单位的整个目标 中心（WU-HTARC）是收集人类肿瘤生物测量，以通过表征和数据使用 分析单位构建所提出的肿瘤图谱。我们的生物循环单位将采购和银行 纵向活检和从300-375例患者中切除的肿瘤（从约750名招募患者中选择） 目的是研究从主要恶性肿瘤到复发和转移的转变 三重阴性乳腺癌（TNBC），胶质母细胞瘤（GBM）和 胰腺导管腺癌（PDAC）。为这项研究选择的三个肿瘤中的每一个都构成独特 临床医生和研究人员都面临挑战。从他们经常诊断后期发作，高度转移 自然，实现完整手术切除方面的挑战以及对治疗的主要和获得的抵抗力， 这些肿瘤中的每一个都代表了NCI癌月份倡议（CMI）确定的机会 显着提高我们对癌症的理解以及如何干预其开始和进展。到 支持WU-HTARC的整体任务，生物传感单元将执行以下操作：（1）识别 WU与TNBC，GBM和PDAC的合格患者； （2）严格而全身收集肿瘤，包括 在整个治疗过程中，所有患者的纵向收集； （3）完整的关联收集 临床数据和元数据； （4）存储和处理所有具有当前和未来实验的样品 和分析管道。 Biospecimen单元将与Wu-Htarc中的其他单位紧密合作以开发 标准操作程序，并根据不断变化的技术进行调整。